71 related articles for article (PubMed ID: 12382028)
21. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
[TBL] [Abstract][Full Text] [Related]
22. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
23. Acridones circumvent P-glycoprotein-associated multidrug resistance (MDR) in cancer cells.
Gopinath VS; Thimmaiah P; Thimmaiah KN
Bioorg Med Chem; 2008 Jan; 16(1):474-87. PubMed ID: 17933543
[TBL] [Abstract][Full Text] [Related]
24. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver.
Arora A; Seth K; Shukla Y
Carcinogenesis; 2004 Jun; 25(6):941-9. PubMed ID: 14729595
[TBL] [Abstract][Full Text] [Related]
25. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P
In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756
[TBL] [Abstract][Full Text] [Related]
26. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
27. Avoidance of doxorubicin resistance in osteosarcoma cells using a new quinoline derivative, MS-209.
Takeshita H; Kusuzaki K; Tsuji Y; Hirata M; Hashiguchi S; Nakamura S; Murata H; Ashihara T; Hirasawa Y
Anticancer Res; 1998; 18(2A):739-42. PubMed ID: 9615713
[TBL] [Abstract][Full Text] [Related]
28. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
[TBL] [Abstract][Full Text] [Related]
29. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
30. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
31. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein.
Kim YK; Song YJ; Seo DW; Kang DW; Lee HY; Rhee DK; Han JW; Ahn CM; Lee S; Kim SN
Biochem Biophys Res Commun; 2007 Mar; 355(1):136-42. PubMed ID: 17286965
[TBL] [Abstract][Full Text] [Related]
32. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
33. P-glycoprotein activity and biological response.
Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
35. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
Ji BS; He L
J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
[TBL] [Abstract][Full Text] [Related]
36. Lobeline, a piperidine alkaloid from Lobelia can reverse P-gp dependent multidrug resistance in tumor cells.
Ma Y; Wink M
Phytomedicine; 2008 Sep; 15(9):754-8. PubMed ID: 18222670
[TBL] [Abstract][Full Text] [Related]
37. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
38. 20S-protopanaxadiol inhibits P-glycoprotein in multidrug resistant cancer cells.
Zhao Y; Bu L; Yan H; Jia W
Planta Med; 2009 Aug; 75(10):1124-8. PubMed ID: 19291609
[TBL] [Abstract][Full Text] [Related]
39. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
40. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Boumendjel A; Di Pietro A; Dumontet C; Barron D
Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
